Multimodality Management of Borderline Resectable Pancreatic Cancer
This volume provides the most comprehensive coverage of clinical management of borderline resectable pancreatic cancer available. Authored by leaders in the field, the book focuses on current clinical management of this disease stage, the importance of mu
- PDF / 25,077,435 Bytes
- 333 Pages / 504.63 x 737.01 pts Page_size
- 9 Downloads / 217 Views
Matthew H.G. Katz Syed A. Ahmad Editors
123
Multimodality Management of Borderline Resectable Pancreatic Cancer
Matthew H.G. Katz • Syed A. Ahmad Editors
Multimodality Management of Borderline Resectable Pancreatic Cancer
Editors Matthew H.G. Katz Department of Surgical Oncology MD Anderson Cancer Center Houston, TX, USA
Syed A. Ahmad Division of Surgical Oncology The University of Cincinnati Medical Center Cincinnati, OH, USA
ISBN 978-3-319-22779-5 ISBN 978-3-319-22780-1 DOI 10.1007/978-3-319-22780-1
(eBook)
Library of Congress Control Number: 2015956343 Springer Cham Heidelberg New York Dordrecht London © Springer International Publishing Switzerland 2016 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper Springer International Publishing AG Switzerland is part of Springer Science+Business Media (www.springer.com)
Preface
Over the past decade, great efforts have been made toward refining the clinical systems used to stage localized pancreatic cancer. As the benefits of the administration of preoperative therapy have increasingly become recognized, and as the performance of vascular resection and reconstruction at pancreatectomy has concurrently become more common, many infiltrative cancers that were historically considered unresectable are now more commonly described as “borderline resectable.” Tumors in this category are those that are technically removable, but which are associated with a significant likelihood of a positive margin when surgery is performed de novo. Given that the overall survival rate of patients who undergo margin-positive operations is similar to that of patients who do not undergo surgery at all, recognition of borderline resectable pancreatic cancer as a unique clinical entity is critical, both for optimal patient care and for the proper evaluation of novel (neo) adjuvant treatment regimens in clinical trials. In this book, we have assembled an internationally recognized group of clinical experts to compile an
